Regeneron Pharmaceuticals has commenced the first clinical trial of its dual antibody cocktail, REGN-COV2, which is intended to prevent and treat Covid-19.

The REGN-COV2 clinical programme will involve hospitalised patients, non-hospitalised symptomatic patients, uninfected individuals in groups at high exposure risk, such as healthcare works, and uninfected people with close exposure to a Covid-19 patient.

Regeneron noted that the placebo-controlled trials will be performed at several sites.

The company analysed numerous fully-human antibodies generated using the company’s VelocImmune mice, along with antibodies isolated from recovered Covid-19 patients.

Based on the findings, the company chose the two most potent virus-neutralising antibodies and scaled them up for clinical use by using its in-house VelociMab and manufacturing capabilities.

According to preclinical research, the selected dual antibodies attach non-competitively to the receptor binding domain (RBD) of the virus’ spike protein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first two adaptive Phase I/II/III trials, REGN10933 and REGN10987, are designed to assess REGN-COV2 for the treatment of hospitalised and non-hospitalised Covid-19 patients.

The Phase I part of the trials will track virologic and safety endpoints, while the Phase II part will focus on virologic and clinical endpoints. The Phase I and Phase II results will help refine the endpoints and determine the size for the Phase III studies.

Regeneron Pharmaceuticals co-founder, president and chief scientific officer George Yancopoulos said: “We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic.

“REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick, and could be available much sooner than a vaccine.”

The antibody cocktail is also expected to show long-term utility for elderly and immuno-compromised patients.

In March this year, Regeneron and Sanofi initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19.